Rate My Professor Yun Fang

Yun Fang is Professor of Medicine at the University of Chicago, with appointments in the Committee on Genetics, Genomics and Systems Biology and the Committee on Molecular Metabolism and Nutrition. He leads an interdisciplinary research program integrating vascular biology, functional genomics, bioengineering, and nanotechnology to investigate how mechanical and biochemical cues regulate gene activity in health and disease. His laboratory examines the convergence of these signals on transcription factors, the non-coding genome, epigenetic and epitranscriptomic modifications, and intracellular signaling pathways, with applications to cardiovascular, fibrotic, and metabolic diseases. The program also develops proprietary nanomaterials for targeted delivery of nucleic acids and small molecules to diseased vascular and stromal cells.

Fang earned a BS in Microbiology and Plant Pathology from National Taiwan University in 1999, an MS in Biotechnology from the University of Pennsylvania in 2002, a PhD in Bioengineering from the University of Pennsylvania in 2006, and completed postdoctoral training in Medicine and Engineering at the University of Pennsylvania in 2012. He joined the University of Chicago faculty and was promoted to Professor of Medicine in 2024. His contributions include the 2026 Judah Folkman Award in Vascular Biology from the North American Vascular Biology Organization, the 2023 Established Investigator Award from the American Heart Association, election as a Fellow of the American Institute for Medical and Biological Engineering and the American Heart Association in 2023, and an NHLBI R35 award in 2022. He serves as Director of the IM Physician Scientist Development Program and Faculty Associate Director of Curriculum for the Medical Scientist Training Program at the University of Chicago, and has held roles such as Co-Chair of the Gordon Research Conference on Biomechanics in Vascular Biology and Disease. Fang’s work has advanced understanding of endothelial mechanotransduction and supported development of nanomedicine platforms for vascular diseases.